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Abstract
The coronavirus disease 2019 (COVID-19) pandemic has generated high interest in factors modulating risk of infection, disease severity and
recovery. Vitamin D has garnered interest since it is known to modulate immune function and vitamin D deficiency is associated with increased
risk of respiratory infections and adverse health outcomes in severely ill patients. There are no population representative data on the direct
relationship between vitamin D status and severe acute respiratory syndrome coronavirus 2 infection risk and severity of COVID-19. Data from
intervention studies are limited to four studies. Here we summarise findings regarding vitamin D status and metabolism and their alterations
during severe illness, relevant to COVID-19 patients. Further, we summarise vitamin D intervention studies with respiratory disease outcomes
and in critically ill patients and provide an overview of relevant patient and population guidelines. Vitamin D deficiency is highly prevalent in
hospitalised patients, particularly when critically ill, including those with COVID-19. Acute and critical illness leads to pronounced changes in
vitamin D metabolism and status, suggestive of increased requirements. This needs to be considered in the interpretation of potential links
between vitamin D status and disease risk and severity and for patient management. There is some evidence that vitamin D supplementation
decreases the risk of respiratory tract infections, while supplementation of intensive care unit patients has shown little effect on disease severity
or length of treatment. Considering the high prevalence of deficiency and low risks associated with supplementation, pro-actively applying
current population and patient management guidelines to prevent, monitor and correct vitamin D deficiency is appropriate.
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Introduction
Coronavirus disease 2019 (COVID-19) is causing worldwide
morbidity and mortality. The aetiology and progression of the
– initially – respiratory disease in those severely affected is com-
plex and affects many organ systems. Disease severity varies
widely between affected individuals, from an asymptomatic
course or mild symptoms to an overwhelming multisystem ill-
ness with high mortality. Those who are older, obese and with
major pre-existing health conditions (including cardiovascular
disease and diabetes) are at greatest risk(1–5). In addition to a high
incidence of acute respiratory distress syndrome (ARDS), the
virus poses particular risks of both arterial and venous thrombo-
embolism and of haemorrhagic complications: pulmonary
embolism and stroke are important causes of death.
Endothelial damage may also contribute to the high incidence
of acute kidney injury (AKI). Immune dysfunction underlies
the catastrophic ‘cytokine storm’ which can be a terminal
event(1,4,6). Several therapeutic interventions, particularly those
that control cytokine production, have recently been shown to
reduce mortality in patients with a severe disease course(4,7–9).
Vaccination programmes are currently rolled out globally.
Until the time that a large proportion of the world population
has acquired immunity, infection prevention and reduction of
disease severity is paramount, in view of the severe disease proc-
ess with long rehabilitation time in many patients(10).
Vitamin D has received increased interest since it is known to
modulate immune function and the inflammatory response and
vitamin D deficiency is associated with increased risk of respira-
tory infections(10–15) and adverse health outcomes in severely ill
patients(16,17). It may therefore be involved in both susceptibility
and progression of respiratory disease. No good-quality, popu-
lation representative data on the relationship between vitamin D
status and severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection risk and severity of COVID-19 exist.
The first findings from three intervention studies in hospitalised
COVID-19 patients supplemented with vitamin D were recently
published(18–20), and several randomised controlled trials (RCT)
in diverse population or patient groups are ongoing(10,21,22).
Vitamin D status is measured as the plasma concentration of
25-hydroxy vitamin D (25(OH)D). Deficiency thresholds for
population health are defined as 25(OH)D serum concentrations
<25 or 30 nmol/L per UK andUS guidelines. Thresholds or target
Abbreviations: 25(OH)D, 25-hydroxy vitamin D; 1, 25(OH)2D, 1, 25-dihydroxy vitamin D; 24, 25(OH)2D, 24, 25-dihydroxy vitamin D; PTH, parathyroid hor-
mone; IGF-1, insulin growth factor 1; FGF23, fibroblast growth factor 23; DBP, vitamin D binding protein.
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values for 25(OH)D may be set higher for clinical management
and specific patient groups(23–25). Vitamin D status has been
shown to be associated with many health outcomes, but for
many chronic diseases other than musculoskeletal health, inter-
vention trials are less consistent and often do not confirm find-
ings of observational studies(26–28). This can potentially be
ascribed partly to the confounding effects of vitamin D supply
from sources other than the intervention given in RCTs (i.e. vita-
min D supply through cutaneous sun exposure and from food
and supplements), vitamin D uptake in and potential mobilisa-
tion from bodily stores and the complex nature of vitamin D
metabolism. Vitamin D status is therefore influenced by factors
associated with lifestyle and fitness. In addition, status is affected
by pathological changes occurring during acute and chronic ill-
ness. Therefore, causality and reverse causality are difficult to
distinguish. Further, the effect of interventions may depend on
baseline and post-supplementation vitamin D status, but also
results considering 25(OH)D before and after supplementation
are conflicting(29–32).
The role of vitamin D and the effect of supplementation has
also been investigated in studies and intervention trials with res-
piratory disease outcomes and critically ill patients. These are
likely relevant for the current COVID-19 epidemic.
Here we summarise recent findings regarding vitamin D sta-
tus and metabolism in patients, with a particular focus on those
severely ill and with COVID-19. The effect of vitamin D supple-
mentation on respiratory disease and critically ill patients is
described in the context of alterations of vitamin D metabolism
and requirements with severe illness. We also provide an over-
view of guidelines to correct and maintain vitamin D status for
specific categories of patients and the prevention of vitamin D
deficiency in population groups.
COVID-19, vitamin D status and supplementation
The recent COVID-19 epidemic identified a high prevalence of
vitamin D deficiency amongst patients(33), particularly those that
develop severe symptoms of the disease(34–39). Vitamin D defi-
ciency (25(OH)D <30 nmol/L) at hospital admission (n= 185)
was associated with increased hazard ratio to require invasive
mechanical ventilation and death in one study(40), but this was
not found in another, slightly smaller study (n= 109)(41).
Patients at increased risk of requiring intensive care unit (ICU)
admission and ventilation appear to be carriers of common risk
factors for vitamin D deficiency, that is, being overweight or
obese, having type 2 diabetes, hypertension and chronic kidney
disease(2,3,36,42), but vitamin D status has also been reported to be
an independent predictor after adjustment for confounding fac-
tors(37,40). This raises the question whether vitamin D deficiency
is a risk factor for this viral infection and/or developing severe
disease symptoms is a biomarker of poorer health or that the dis-
ease process is associated with a decrease in vitamin D status as
outlined below. In several countries (the United States and UK),
overrepresentation of ethnic minorities testing positive and/or
developing severe symptoms is reported(3,39,43–46) (https://
digital.nhs.uk/coronavirus/coronavirus-data-services-updates/
ethnicity-and-outcomes-of-covid-19-patients-in-england). The
higher prevalence of severe illness in specific ethnic minority
groups in the United States and UK, countries with temperate cli-
mates, has been suggested to be related to their generally lower
vitamin D status, due to lower rate of cutaneous vitamin D pro-
duction associated with a darker skin tone. Many other factors
may also play a role, including higher risk of obesity, hyperten-
sion, type 2 diabetes mellitus, elevated inflammation markers
and renal impairment, in these groups(47). Individuals of specific
racial descent may potentially also have different responses to
infection and treatment andmay require different treatment strat-
egies. In addition, overrepresentation of these groups in profes-
sions with high exposure risk, differences in access to and use of
health care systems and other socio-economic factors may play a
key role in some areas(45,48). Country differences in the preva-
lence of COVID-19 between ethnic groups may also reflect
differences in population diversity and characteristics and health
care systems. There are no prospective data available that
directly allow the investigation of the protective role of vitamin
D status, intake and supplementation in the prevention of infec-
tion with SARS-CoV-2 at the time of viral exposure and sub-
sequent development of COVID-19 symptoms. Two studies
with retrospective data from the population-based UK
BIOBANK showed that plasma 25(OH)D measured 10–14 years
before the COVID-19 outbreak was not associated with the risk
of developing moderate-to-severe symptoms of the disease after
correction for appropriate confounders(44,49,50). In univariate
models, Hastie(50), but not Raisi- Estabragh found an increased
odds ratio of COVID positivity with lower plasma concentrations
of 25(OH)D, but this did not remain significant after correction
for range of confounders (BMI, age, ethnicity and season) and
co-morbidities. Other retrospective studies used large data sets
from clinical laboratories and medical records. Kaufman
et al.(46) reported a significant negative association between
the percentage of patients testing positive for SARS-CoV-2 and
season-corrected plasma 25(OH)Dmeasured within a year prior
to SARS-CoV-2 infection. In subgroup analyses, Kaufman pre-
sented data by ethnic group (as based on predominance of eth-
nicity by postcode area), showing (a) a higher COVID positive
incidence rate and (b) a lower plasma 25(OH)D concentration
in postcodes with predominantly Black and Hispanic commun-
ities compared with predominantly white communities, but (c)
the association with 25(OH)D was negative and significant in
all three groups. Meltzer conducted two retrospective studies
using large data sets from clinical laboratories and medical
records. They included individuals who had a COVID-19 PCR
test following potential COVID-19 symptoms or exposure and
if assessed for vitamin D status within 1 year before the
COVID test. In the 2020 study by Meltzer(51), this was based
on plasma 25(OH)D or 1,25(OH)2D concentrations. In the larger
(n= 4638), 2021 study, this was based on 25(OH)D only(39,51).
An increased risk of testing positive with lower category of vita-
min D status (values below versus above 50 nmol/L(51) and
below 50 nmol/L versus ≥100 nmol/L(39)) was reported in both
studies. In subgroup analyses by ethnicity and controlling for a
range of confounders and co-morbidities as well as time since
last 25(OH)D test, Meltzer(39) reported an increased risk of infec-
tion (incidence rate ratio (IRR) 2·55; 95% CI, 1·26–5·15) in African
Americans with a 25(OH)D below 50 nmol compared with those
with a concentration over 100 nmol/L (<20 versus >40 ng/mL).
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The relationship between the COVID-19 IRR and 25(OH)D was
non-linear and non-significant for the category 50–75 nmol/L
compared with ≥100 nmol/L. This association with 25(OH)D
was not found in white counterparts. The results from
Kaufman and Meltzer suggest that there may be an interaction
between ethnicity, vitamin D status and COVID-19 risk.
However, differences between ethnic groups in the relative risk
of infection and association with vitamin D status may also be
determined by other factors that differ by ethnicity as outlined
above. Such associations between COVID infection risk and vita-
min D status may be lost in those reports that applied statistical
adjustment for ethnicity(50), since in temperate climates, vitamin
D status differs by ethnic group. Another study (Israel; subtropi-
cal region) reported an increased odds ratio for infection and
hospitalisation with COVID-19 amongst patients who had a
plasma 25(OH)D below 75 nmol/L tested before the COVID-
19 outbreak(52). In this study, it was unclear how long before
the outbreak and in which season this prior test of 25(OH)D
was done. Both Kaufman and Merzon(46,52) did not correct for
body composition nor provide data whether treatment of vita-
min D deficiency was initiated after testing, a factor considered
in the two studies by Meltzer(39,51).
There are several limitations to these prospective population-
based studies and the use of medical records. Changes in recom-
mendations for vitamin D intake and testing for and correction of
deficiencymay have resulted in secular trends in population vita-
min D status. In the UK, however, population vitamin D status
did not substantially change after the 2016 revised guidance
(https://www.gov.uk/government/collections/national-diet-
and-nutrition-survey). Although vitamin D status is known to
track within a person, it is strongly influenced by season. In tem-
perate climates, like the UK, population vitamin D status typi-
cally cycles with the seasons, with a nadir in March and a
peak in September(53). The nadir thus coincides with the peak
of many respiratory viral infections, but also other factors play
a role, including meteorological factors (temperature, UV index,
humidity) influencing virus survival and time spent indoors(54,55).
It may therefore be reasonable to assume that vitamin D status at
the time of viral exposure may be the more relevant measure
than a year average or season-adjusted value. Another study,
relating the severity of the COVID outbreak with latitude and
season also suggested a role of vitamin D status(56,57).
However, the subsequent spread of the virus across all climate
zones and the resurge of COVID prevalence in September 2020
and summer 2021 at northern temperate latitudes does not
appear to strongly support this hypothesis. Data frompopulation
studies, such as the Biobank studies(44,49,50), are further limited by
the fact that those typically at increased risk of being exposed or
developing severe COVID-19 symptoms (i.e. ethnic minority
groups and older frail people) are often underrepresented in
population surveys(45,48), while in data sets based on medical
records, individuals with underlying health conditions may be
overrepresented. In addition, in clinical data sets that are
restricted to patients with a prior biochemical test of 25(OH)
D, individuals with an increased risk of deficiency and receiving
treatment are expected to be overrepresented. Changes in vita-
min D status following testing and treatment also need to be con-
sidered. Notwithstanding, generating ‘optimal’ data to assess the
protective role of vitamin D status would require near-impos-
sible intense surveillance and sampling of large cohorts of peo-
ple potentially acquiring the infection.
Findings of the first small, open-label vitamin D intervention
trial (n= 50 intervention; n= 26 control group) with hospitalised
COVID-19 patients in Spain (diagnosed by positive PCR test and
radiographic evidence of viral pneumonia) was recently pub-
lished(18). In this study, which was a sub-study COVIDIOL
cohort, an intermediate high oral dose of calcifediol (the phar-
maceutical form of 25(OH)D) at hospitalisation and at regular
intervals thereafter was provided. The control group received
standardmedical care without vitaminD. In the vitaminD group,
the risk of ICU admission was significantly reduced (OR 0·02;
95% CI 0·002–0·17), but this was based on one patient in the
intervention group and thirteen in the control group requiring
ICU treatment. In this study, a range of prognostic indices and
risk factors for the development of severe symptoms were inves-
tigated. Compared with the intervention group, there was a
higher prevalence of potential risk factors for the development
of severe COVID in the control group (hypertension: 24% versus
58 %, P= 0·002; diabetes mellitus 6 % versus 19 %; P= 0·08).
After correction for these potential confounding factors,
differences in the OR remained significant (OR 0·03; 95% CI
0·003–0·25). Baseline and post-supplementation vitamin D sta-
tus was not assessed, and potential confounding by body com-
position was not considered. Differences in deaths were also
investigated and were not significant. However, interpretation
of this outcome was hindered by the design the study, by which
supplementation was stopped on admission to ICU. Nogues(20)
reported a second sub-study from the COVIDIOL cohort includ-
ing a larger data set (n= 447 intervention; n= 391 control
group). Interventions were identical, but in this sub-study, sup-
plementation was continued after ICU admission. Baseline
25(OH)D was 32·5 (IQR 20–55) nmol/L. Co-morbidities were
well balanced, except for a slightly lower baseline 25(OH)D con-
centration in the control group. This study also showed a
reduced risk of ICU admission with and without adjustments
for confounders, which included baseline 25(OH)D (con-
founder adjusted OR 0·13; 95% CI 0·07–0·23). Mortality was sig-
nificantly reduced in the calcifediol-supplemented group
(confounder-adjustedOR 0·21; 95% CI 0·10–0·43). A randomised
placebo-controlled vitamin D intervention trial in Brazil (n= 120
intervention; n = 120 placebo) with hospitalised COVID-19
patients (diagnosed by positive PCR test) administered a single
dose of 200,000 IUD3 1·4 d after admission and 10·3 d after onset
of symptoms. Mean baseline 25(OH)Dwas 52 ± 9·1 nmol/L. This
trial did not result in a reduction in length of hospitalisation, in-
hospital mortality, risk of ICU admission or requiring mechanical
ventilation(19). Rastogi(58) investigated the 21-d SARS-CoV-2
clearance rate in mildly symptomatic or asymptomatic individ-
uals with a 25(OH)D< 50 nmol/L (median baseline concentra-
tion <25 nmol/L). Supplementation was open label and
individually tailored to achieve a 25(OH) concentration over
50 nmol/L. They reported a higher proportion of patients who
were SARS-CoV-2 negative after 21 d in the supplemented group
(n= 10 of 16; 62·5 %) versus the placebo group (n= 5 of 24; 20·8
%), although the mean duration to being SARS-CoV-2 negative
was not different between groups. No data were presented on
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the severity of symptoms or length of hospitalisation, and no data
on risk factors.
Time from onset of COID symptoms was only reported in the
study by Murai (10·3 ± 4·3 d); Nogues(20), Entrenas Castillo(18)
and Murai(19) reported time from hospitalisation to supplemen-
tation (0, 0 and 1·4 (0·9 d) d, respectively). Considering the
potential multifactorial role of vitamin D (and thus status and
supplementation) in different stages and aspects of the response
to viral infection and subsequent development of symptoms,
time since infection and development of (severe) symptoms rel-
ative to the start of supplementation as well as baseline 25(OH)D
concentrationsmay be important factors to consider in the evalu-
ation of the effect of interventions. This is supported by secon-
dary outcomes reported by Nogues(20). They found that, when
mortality rates were considered including both patients that ini-
tiated calcifediol treatment at hospitalisation (n= 447) and those
that first received this at ICU admission (n = 53), the adjusted
mortality OR (0·52; 95%CI 0·27–0·99)was higher thanwhen only
patients were considered that initiated treatment at admission.
The authors speculated that supplementation is more effective
if initiated before the development of ARDS.
Though not randomised, an audit of standard care in a
French nursing home found that residents who had received
regular 2–3 monthly vitamin D supplementation (oral 80,000
IU as a bolus) within 1 month before or 1 week after SARS-
CoV-2 virus infection had a less severe disease course and
lower mortality(59). Similarly, an audit of vitamin D supplemen-
tation in frail hospitalised COVID-19 patients, showed a lower
mortality risk in those that who had received regular vitamin D
supplementation preceding infection and in those supple-
mented directly after testing positive (both 80,000–100,000 IU
as a bolus) compared with those who did not receive vitamin
D supplementation(60).
Upper respiratory tract infections and vitamin D status
and supplementation
Observational studies have shown that vitaminD deficiencymay
predispose to increased risk of viral acute respiratory tract infec-
tions. Findings of the effect of vitamin D supplementation on the
risk of preventing acute respiratory tract infections are conflict-
ing. Meta-analyses of RCTs and recent RCTs indicate that daily
supplementation (intakes of 400–1000 IU/d) has a small protec-
tive effect(10,11,14,15,61). No protective effect was found with less
frequent (weekly or less or after a bolus) administration. Many
of the studies were conducted in populations with pre-existing
respiratory diseases and in children. The most recent and largest
meta-analyses found no interactionwith 25(OH)D concentration
at baseline(61), whereas in an earlier individual participant data
meta-analyses, a stronger protective effect was found in sub-
groups with baseline vitamin D deficiency (<25 nmol/L)(11,62).
The two UK Scientific Advisory Committee on Nutrition
(SACN) rapid reviews on vitamin D and acute respiratory tract
infections concluded that there is evidence of a small beneficial
effect of vitamin D supplementation with intakes of
400–1000 IU/d, but that sufficient evidence is only available
for children 1–16 years of age (https://www.gov.uk/
government/publications/sacn-rapid-review-vitamin-d-and-
acute-respiratory-tract-infections). A recent study in long-term
care residents, with approximately one-third of participants with
a baseline 25(OH)D< 50 nmol/L, showed a significant protec-
tive effect (odds ratio 0·67) with high-dose monthly supplemen-
tation (100,000 IU per month). However, in this study, consistent
with other reports with high-dose bolus vitamin D supplemen-
tation, an increased risk of falling was observed(13).
Evidence from a large multi-centre observational study in
infants hospitalised for bronchiolitis suggests that vitamin D sta-
tus is associated with severity of respiratory disease. This study
showed that the percentage of hospitalised children that pro-
ceeded to need intensive care treatmentwas almost twice as high
in those with a 25(OH)D< 50 nmol/L compared with those with
a concentration >75 nmol/L (22 % versus 12 %)(63). Vitamin D
intervention studies in children with pneumonia have, however,
not shown a reduction of length of recovery and other disease
outcomes(63).
Mechanistic studies support a role of vitamin D and its metab-
olites and vitamin D binding protein (DBP) in immune function
and pulmonary health, which is summarised below. The con-
trasting findings between observational, mechanistic and inter-
vention studies suggest that many other factors play a role; the
beneficial effects of vitamin D may be limited to specific sub-
groups, the alterations in vitamin D metabolism with disease
processes may influence its function and/or other drivers of
the immune and inflammatory response may be predominant,
particularly in severe illness.
Summary of interactions of vitamin D metabolites and
vitamin D binding protein with respiratory tract infections
and immune function
The effect of vitamin D and DBP on immune function and pul-
monary health has been described in in vitro, ex vivo and animal
models and in human health(64). It is considered to be multi-fac-
torial and involves both the innate and adaptive immune func-
tion (see reviews(10,64,65)). Laboratory studies indicate that the
active metabolite 1,25-dihydroxy vitamin D (1,25(OH)2D) mod-
ulates the expression of angiotensin-converting enzyme 2
(ACE2), the receptor for SARS-CoV, including SARS-CoV-2,
and may thus modulate viral entry and infection(10,56). To date,
it is unclear what the importance of this mechanism is.
Vitamin Dmetabolites and DBP appear to play an important role
in the immune and inflammatory response and, hence, disease
severity and the development of immunity. It may also be
hypothesised that vitamin D status modulates the response to
vaccination. Many of the cells of the immune system and those
with a barrier function, express vitamin D receptors (VDRs) and
CYP27B1, the enzyme that hydroxylates 25(OH)D into
1,25(OH)2D. This locally produced 1,25(OH)2D activates
VDRs for autocrine and paracrine functions. It stimulates the
expression of the antimicrobial function of cathelicidin, which
modulates the chemokine and cytokine response and stimulates
the chemotaxis of neutrophils, monocytes and T cells, thus pro-
moting the clearance of respiratory pathogens(10,64–66). Further,
25(OH)D and 1,25(OH)2D stimulate autophagic encapsulation
of viral particles, promoting lysosomal degradation and antigen
presentation(65). The role of vitamin D deficiency and
4 Inez Schoenmakers et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0954422421000251
Downloaded from https://www.cambridge.org/core. University of East Anglia (UEA), on 22 Oct 2021 at 07:26:58, subject to the Cambridge Core terms of use, available at
supplementation in lymphocyte differentiation and apoptosis
remains unclear(67,68), but considering that severe illness with
COVID-19 is characterised by inadequate T-cell responses(1,69),
it may be expected that the effects of vitamin D metabolites on
immune function with severe COVID are altered. It may there-
fore be speculated that vitamin D status is of particular impor-
tance in earlier stages and the progression of the disease,
preventing the development of a cytokine storm, found in
patients with a severe disease course of COVID-19(10,64).
Vitamin D deficiency has also have been linked to increased risk
of the development of endothelial dysfunction and cardio-
vascular complications, frequently observed in patients hospital-
ised with COVID-19. Although no direct casual evidence is
available, mechanistic studies suggest that deficiency or reduced
VDR activation leads to overexpression of the renin– angiotensin
aldosterone system (RAAS), hypertension and increased throm-
bogenicity(65). This may influence the effects SARS-CoV-2 infec-
tion and its interaction with the ACE2 receptor, suggested to lead
to dysregulation of RAAS(65,70).
Summary of vitamin D metabolism
Vitamin D metabolism
Vitamin D is synthesised in the skin after sunshine exposure and
taken up into the lymph system. In temperate climates this only
occurs during spring and summer months, whereas at latitudes
<30° north and south this can take place throughout the year.
Oral vitamin D is rapidly and efficiently absorbed from the intes-
tine incorporated in chylomicrons. Vitamin D from both supply
routes is transported to the liver, but part of it may be taken up by
fat tissue. In the liver, vitaminD is converted to 25(OH)D (Fig. 1).
Despite the efficient conversion (˜80 % at first passage with nor-
mal liver function), it takes several days to weeks to correct vita-
min D deficiency unless high (bolus) dosages are given,
particularly in severely deficient patients with a high BMI. This
is thought to be due to the uptake of vitamin D by fat cells.
Oral supplementation with 25(OH)D (i.e. calcifediol), at present
only available on prescription, leads to a faster (with an increase
already detectable within a few hours after administration) and
proportionally higher increase in plasma 25(OH)D(71).
A further conversion into the active metabolite 1,25(OH)2D is
required, and this occurs in the kidney for systemic effects. Local
conversion takes place in many other tissues for autocrine and
paracrine effects, including the lung and cells of the immune sys-
tem. The regulation of 1,25(OH)2D production in the kidney is
predominantly under control of parathyroid hormone (PTH),
1,25(OH)2D itself, fibroblast growth factor 23 (FGF23) and sev-
eral other factors, including sex hormones (reviewed in Ref.(71)).
The extra-renal production is not under the control of these fac-
tors, except for FGF23. Instead, its regulation is thought to be tis-
sue specific and is only partly understood. In immune cells, the
regulation of 1,25(OH)2D production is partly influenced by
inflammatory factors and cytokines (reviewed in Refs.(10,64,72))
(Fig. 1).
Generally, there is no or a poor correlation between plasma
concentrations of 25(OH)D and 1,25(OH)2D. The concentration
below which 25(OH)D becomes rate limiting for 1,25(OH)2D
production is not well established and also depends on other fac-
tors. It is generally assumed that when 25(OH)D falls below
15 nmol/L, plasma 1,25(OH)2D is reduced(71). A meta-analysis
of supplementation studies, however, showed that post-supple-
mentation 1,25(OH)2D concentrations also increased when
baseline 25(OH)D concentrations were above 15–20 nmol/
L(73). It is unclear whether at lower 25(OH)D concentrations
the balance between renal and extra-renal 25(OH)D availability
and tissue uptake is altered. In the kidney, internalisation of
25(OH)D, bound to its binding protein is through an active meg-
alin–cubilin receptor mediated mechanism. It may therefore be
assumed that renal uptake takes place against the concentration
gradient, partly overcoming the effects of low plasma 25(OH)D
availability. In most other tissues, including those pertaining to
the immune system, a receptor-mediated internalisation mecha-
nism has not been demonstrated. According to the free hormone
theory, cellular uptake in these extra-renal tissues is thought to
be concentration dependent and thus is reducedwhen 25(OH)D
is low (see further below).
The role of vitamin D binding protein in vitamin D
metabolism
The majority of vitamin D and its metabolites circulate in plasma
bound to DBP (˜85–90 %) and to a lesser extent and with a lower
binding affinity to albumin. Less than 1 % circulates in its free
form(71). In healthy people, the free 25(OH)D concentration is
highly correlated to total 25(OH)D and accordingly, the free:
total 25(OH)D ratio is stable throughout the physiological ranges
of 25(OH)D(74). In some physiological and pathological condi-
tions, the free 25(OH)D fraction is altered, and this is thought
to be predominantly a result of changes in the concentrations
of DBP(74). DBP binding of vitamin D metabolites has several
functions: to prolong half-life and to facilitate cellular internalisa-
tion of vitaminDmetabolites through themegalin–cubilin recep-
tor pathway. The megalin–cubilin receptor is expressed in a
number of other tissues and is not specific to the DBP–vitamin
D complex. Internalisation of vitamin Dmetabolites through this
pathway has to date only been shown in renal and muscle tissue
and potentially in the mammary gland. Other tissues, including
those pertaining to the immune system are thought to be mostly
dependent on the internalisation of the free fraction. However,
other internalisation mechanisms for 25(OH)D and 1,25(OH)2D
have been proposed, andDBP also plays an important role in the
delivery and distribution of compounds to all tissues(75).
The megalin–cubilin mediated internalisation of the DBP-
25(OH)D complex is thought to be the predominant internalisa-
tion route in the kidney and is also essential for renal reabsorp-
tion of the DBP complex and thus prevents urinary losses of both
the protein and the associated vitamin Dmetabolites. A decrease
in the expression of these receptors with renal impairment is
associated with a decline in systemic 1,25(OH)2D concentra-
tions. It may be speculated that also a reduction of plasma
DBP may lead to a reduction in renal bioavailability of vitamin
D metabolites, reducing the substrate for production of systemic
1,25(OH)2D.
DBP binding protects against catabolism of vitamin D metab-
olites. As a consequence, in conditions with a decreased DBP
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concentration, although this has never beenmeasured directly, it
is expected that the bodily stores of 25(OH)D are more rapidly
depleted and that the half-life of 25(OH)D and the active
metabolite 1,25(OH)2D decreases. This potentially explains
the decrease in vitamin D status during acute illness and the fre-
quently observed poor vitamin D status in ICU patients, even in
those who do not have the traditional risk factors and may have
adequate vitamin D intake. These mechanisms may also partly
explain the low and decline in 1,25(OH)2D concentrations
observed in many ICU patients as described in the next sections.
DBP further fulfils several other functions in the immune sys-
tem and in response to inflammation and tissue damage as sum-
marised below(71,75,76).
Regulation of the concentration and production of
vitamin D binding protein
Vitamin D binding protein is mainly produced in the liver,
although the gene and protein are also expressed in very low
concentrations in other tissues, including monocytes(77). It has
three domains. The ‘A’ domain binds vitamin D metabolites
and the B and C domains actin, and this can occur simultane-
ously(76). The estimated daily production of DBP is about 700–
900 mg/d for an adult (10 mg/kg/d). The plasma concentration
of DBP in healthy people is in the micromolar range (˜6 μmol/L
or 300mg/L) and is remarkably stable throughout the life course.
After acute depletion, for example after trauma or plasma
exchange, DBP returns to baseline values after several days(78).
Reported mean plasma concentrations in healthy populations
vary between 200 and 600 mg/L. These differences are probably
mostly related to assay differences and lack of standardisation.
Some (monoclonal) assays report lower values for specific pop-
ulation groups due to their incomplete quantitation of specific
genotypes of DBP(79).
Similar to albumin, 40 % of DBP is intravascular and 60 % is
distributed in the interstitial space of various organs (primarily
muscle, adipose tissue, connective tissue and skin). It is also
present in bronchoalveolar, amniotic, cerebral and seminal fluid,
breast milk and saliva and bound to the cell surface of many cell
types, including neutrophils(76,77,80).
In humans, exposure to oestrogens increases serumDBP, but
androgens have no effects. Vitamin D status (including defi-
ciency and excess) and supplementation have no effect on
serumDBP concentration. In vitromodels showed that dexame-
thasone, interleukine-6 (IL-6) and tumour necrosis factor alpha
(TNFα) stimulate, while transforming growth factor beta
(TGFβ) inhibits its production(81). Accordingly, DBP hepatic pro-
duction was reported to increase in trauma patients(82). Although
acute inflammation decreases plasma DBP concentrations, in
states of chronic low-grade inflammation such as in obesity
and rheumatoid arthritis, comparable or slightly higher DBP con-
centrations are reported, suggesting that increased hepatic
Fig. 1. Determinants of the kinetics of vitamin D and potential changes with severe illness and treatment. Blue arrows indicate metabolic pathways of vitamin D and
vitamin D metabolites. Letters indicate hydroxylation enzymes: A, CYP2R1; B, CYP27B1; C, CYP24A1. Changes associated with severe illness lead to pronounced
changes in supply, distribution, hepatic conversion, renal losses and metabolism due to changes in hydroxylation enzyme activity. Determinants of these changes are
summarised. Conversion (A) of vitamin D into 25(OH)Dmay be impaired, activation (B) of 25(OH)D into 1,25(OH)2Dmay be decreased, and catabolism (C) of 25(OH) D
into 24,25(OH)2D and 1,25(OH)2D into1,24,25(OH)3D and further downstream productsmay be increased. Metabolismmay further be influenced bymedication use. For
further explanation, see text. Vitamin D metabolism is further influenced by physiological factors and life stage, including growth, pregnancy and ageing
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production compensates for the potential higher degradation
rate of DBP.
Decreased serum DBP concentrations are found in patients
with liver cirrhosis, with protein-energy restriction and malnutri-
tion, peritoneal dialysis, nephrotic syndrome and a variety of
other kidney diseases with proteinuria and renal loss of
DBP(74,76,83,84). Plasma DBP is also decreased in conditions asso-
ciated with cell lysis and the release of intracellular actin into the
bloodstream such as during infection or trauma(85–87). This
decline in DBP reflects its role as actin scavenger protein(76,83,88).
The role of vitamin D binding protein and vitamin D in
actin scavenging and coagulation
Actin is the most abundant intracellular protein in any organism.
During tissue injury, actin is released into extracellular fluids.
Intra-cellular actin exists in two states: monomeric globular actin
(G-actin) or G-actin polymerised into filaments (F-actin)(72). The
process of polymerisation and depolymerisation is dynamic and
highly regulated by actin binding proteins. When released into
the extracellular space, actin escapes normal intracellular regu-
latory mechanisms and the protein will form F-actin filaments. In
animal models, extracellular F-actin filaments have been shown
to alter the coagulation and fibrinolytic systems, leading to occlu-
sion and damage of the microcirculation, particularly in the
lung(72). Actin scavenging by DBP, together with gelsolin, plays
an important role in the clearance of actin from the circulation
and the prevention of formation of actin filaments. In addition,
DBP, particularly when bound to actin, has a regulatory function
in neutrophil chemotaxis and, after conversion to macrophage
activating factor, in macrophage activation(10,72). The function
of DBP as a neutrophil chemotactic cofactor is modulated by
1,25(OH)2D-DBP binding(72). Much of the mechanisms are still
poorly understood(10,72,77,89).
Upon DBP binding of actin, the complex is rapidly catabol-
ised, decreasing DBP plasma half-life from 1·7–3 d to 30
min(76,83,88). Bound vitamin D metabolites are released, and
although they may rapidly re-associate with another DBP mol-
ecule, the free fraction of vitamin D metabolites increases.
This may be a beneficial response to infection, increasing the
availability of vitamin D metabolites for passive cellular internal-
isation, which may particularly increase the uptake into extra-
renal tissues.
Strategies to improve DBP plasma concentrations in patients
through stimulation of endogenous production or intra-
venous administration have not been tested in humans.
Administration of (human) DBP to healthy animals was not asso-
ciated with toxic effects, except the formation of antibodies
against the human form of DBP(90). In vitro models have, how-
ever, shown that exposure to the actin–DBP complex causes
inflammation and cell death(91). The safety profile may therefore
depend on the presence of actin in the extracellular space.
Therefore, caution is warranted with strategies to rapidly and
extensively increase the DBP concentration in the presence of
extracellular actin as this may increase the inflammatory
response(72).
Vitamin D status and metabolism in acute and critically ill
patients
Vitamin D deficiency is commonly found in critically ill patients
of all ages(63,85,87,92–96) and is associated with increased mortality
and morbidity(16,17). It is unclear whether vitamin D deficiency in
these patients is a marker of (pre-existing) poor health or low
supply prior to hospitalisation (due to limited opportunities
for spending time outdoors and/or low dietary intake), or devel-
ops as a result of alteredmetabolism, or whether low tissue avail-
ability plays a role in the disease process. In many but not all
studies, a decrease in 25(OH)D is reported over the course of
hospitalisation(16,85,87,97–101). Also, a lower plasma 1,25(OH)2 D
concentration compared with matched controls and a decrease
in 1,25(OH)2 D is reported in critically ill patients and in patients
undergoing major surgery(16,95,97,102–105).
In a longitudinal observational study, Ney(16) showed that pre-
operative 1,25(OH)2 D concentrations in patients undergoing
major cardiac surgery was a negative predictor of post-operative
organ failure, sepsis, mortality and prolonged hospital stay,
whereas pre-operative 25(OH)D was not predictive. Although
the relationship with post-operative 1,25(OH)2D with health out-
comes was not reported, pre- and post-operative concentrations
seemed to be correlated, and those with low pre-operative values
had a further decline in 1,25(OH)2D. This parallels findings of a
study in ICU patients treated with a high bolus dose of vitamin
D. Post-hoc analyses showed that the 1,25(OH)2 D concentration,
not 25(OH)D, measured in plasma 3 d after vitamin D administra-
tion was predictive of 28-d survival(99). This indicates that renal
activation of 25(OH)D into (systemic) 1,25(OH)2D and mainte-
nance of plasma 1,25(OH)2D concentrations play a key role.
Several mechanisms provide potential explanations (for a
summary, see Fig. 1). Renal impairment and AKI are highly
prevalent in ICU patients. This is also found in patients with
severe COVID-19 symptoms. Renal damage reduces the capac-
ity to convert 25(OH)D into 1,25(OH)2D(106,107) and leads to
renal losses of vitamin D metabolites bound to DBP and albu-
min(87,102). Further, animal models of sepsis show that renal
1,25(OH)2D production may have decreased as a result of
decline in insulin growth factor 1 (IGF-1; known to stimulate
1,25(OH)2D production), despite an increase in PTH, commonly
observed in sepsis. Catabolism may be expected to be increased
due to an increase in FGF23 (known to decrease the half-life of
1,25(OH)2D). Finally, the decline in DBP observed with acute
and critical illness (see further below) is expected to be associ-
ated with an increase in the free fraction and, therefore, catabo-
lism of vitamin D metabolites(71).
An alternative explanation for the decrease in 1,25(OH)2D
concentrations is a functional down-regulation of the total con-
centration tomaintain free 1,25(OH)2 D concentrations constant.
This is observed in several studies conducted after surgery,
where the free fractions of 25(OH)D and 1,25(OH)2D remained
constant in the presence of a decrease in DBP(108,109). A longi-
tudinal study in ICU patients, however, showed that the decline
in 1,25(OH)2D and 25(OH)D far exceeded the decline in DBP,
rendering the free fractions of these metabolites significantly
lower than in healthy controls(105).
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Severe trauma (e.g. hip fracture), major surgical procedures
and severe illness (including septic shock, ARDS) lead to pro-
nounced changes in DBP concentrations(85–88). Although not
detailed in most reports, this should be assumed to reflect
the actin-free DBP concentration, which is measured in most
types of assays. Where total DBP is measured, the concentra-
tion has been reported to increase(88). In two longitudinal stud-
ies in ICU or patients with severe trauma, the total
concentration or actin free DBPwas shown to initially decrease,
while the complexed DBP concentration increased.
Subsequently, measured over the course of 7–10 d, actin-free
and actin-bound DBP concentrations increased(82,105). Plasma
concentrations of DBP (either measured as total, actin-free or
actin-bound) are reported to be a sensitive predictor of in-hos-
pital complications, including sepsis and respiratory distress
and failure, and of mortality(72,80,82,88,110–114). These data indi-
cate that DBP actin binding capacity and hepatic DBP produc-
tion in severely ill patients play an important role in survival. It
has been hypothesised that, when actin release exceeds DBP
scavenging capacity, the formation of actin filaments leads to
increased viscosity and increased risk of coagulation(80,86,105).
Considering that DBP is also present in alveolar fluids, its
involvement in the prevention and development of airway
obstructions may be expected(77,80), although the role of DBP
and change in DBP concentrations with cell lysis and inflamma-
tion in extra-vascular fluids are mostly unknown.
Venous and arterial thromboembolic events are common in
ICU patients and those with severe COVID-19, affecting
approximately 30 % of cases admitted to intensive care and
occurring despite thromboprophylaxis(56). In pre-clinical stud-
ies, vitamin D has been shown to have anti-thrombotic effects,
and there has been considerable interest in the effects of vita-
min D on coagulation, but large intervention studies have failed
to show an impact of vitamin D status or supplementation on
the risks for thromboembolism or cardiovascular disease(10).
This is possibly related to the earlier described reduced capac-
ity to convert 25(OH)D into 1,25(OH)2D in patients typically at
increased risk and depletion of actin scavenging capacity of
DBP and gelsolin and the concomitant decrease in plasma albu-
min concentration, which are not influenced by vitamin D
supplementation(106,107).
Other aspects of altered metabolism, tissue distribution and
extracellular volume also need to be considered in the interpre-
tation of plasma concentrations of vitamin D metabolites, DBP
and the potential of receptor activation. Treatment protocols
of ICU and surgical patients (e.g. fluid load) may lead to signifi-
cant haemodilution; the distribution of compounds between the
vascular and extra-vascular compartments may be changed; and
alterations of tissue uptake and receptor expression may modify
sensitivity and changes of circadian rhythms (well known to play
an important role in vitamin D metabolism and calcium and
phosphate homeostasis(115)), all of which may lead to pro-
nounced changes in plasma concentrations of any biochemical
marker(116–118). All these factors and mechanisms may have
implications for the interpretation of findings in ICU patients
and potential treatment strategies.
Randomised controlled trials with vitamin D in ICU and
acutely ill patients
There is a limited number of published RCTs with administration
of native vitamin D(104,119–125), the pharmaceutical form of
25(OH)D (calcifediol) or 25(OH)D(105) or 1,25(OH)2D(126) in
critically ill patients. In the majority of studies, vitamin D or
25(OH)D was given as either a high bolus or a loading dosage
followed by lower maintenance doses. This strategy is chosen
when time is critical and has been shown to lead to a rapid cor-
rection of vitamin D deficiency(71,105). These trials were designed
(and powered) for different primary and secondary outcomes,
and the majority were of small size (n< 100) and differed in
study population. These trials reported conflicting results.
Several meta-analyses were conducted and focused on hard
clinical end points. Jointly, meta-analyses of these trials showed
no effect on length of hospital or ICU stay and/or requirement for
mechanical ventilation(127–130). No effect on mortality (total 28-d
or split by mortality in hospital or ICU; mortality after 7 d, 28–30
d, 84 d and 6 months) was reported in three of the meta-analy-
ses(128–130), while Putzu(127) reported a lower odds ratio (0·70 CI:
0·50–0·98) for total mortality (as recorded at the last day of data
collection of an individual study) with vitamin D supplementa-
tion. The largest, recent multi-centre RCT (n = 1360)(123) was
only included in the meta-analyses conducted by Lan(128). This
RCT recruited vitamin-D-deficient (defined as 25(OH)
D< 50 nmol/L) patients at high risk of death or lung injury,
and a bolus of vitamin D (540,000 IU D3) was given within 12
h after ICU admission. This trial found no effect on 28- or 90-d
mortality, days on ventilation and length of stay in hospital or
other health care facilities, and none of the wide range of other
health outcomes and measurements (which included the per-
centage of patients that developed ARDS) reached statistical sig-
nificance. The trial, originally designed to recruit 3000 patients,
was stopped on the basis of interim analyses predicting no effect
of treatment.
Trials varied in form, dosages, frequency and length of ad-
ministration of vitamin D or its metabolite. The route of admin-
istrationwas oral, intra-venous or intramuscular. Considering the
differences in pharmacokinetic profiles and bio-availability as
influenced by the form of vitamin D (native or its metabolite(s)),
dosage, frequency and length of administration and route of ad-
ministration (reviewed in Ref.(71)), this may be expected to have
influenced the results of individual trials. The majority of studies
administered a bolus or provided vitamin D for a short length of
time. Twometa-analyses analysed the influence of factors affect-
ing the pharmacokinetic profiles. In these, no significant interac-
tion was found between outcomes and route, length and dose of
administration(128,130). However, the validity of outcomes
reported after more than five times the half-life of either
25(OH)D or 1,25 (OH)2D is questionable (25(OH)D: ˜ 2–3
weeks; 1,25(OH)2D: ˜ 5 h), unless these were reported as cumu-
lative data. In addition, administration of bolus dosages,
although leading to a rapid increase in 25(OH)D, has a disadvan-
tageous pharmacokinetic profile as set out below in the section
‘Symptoms and correction of vitamin D deficiency’. Studies
designed to initially rapidly correct vitamin D deficiency,
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followed by amaintenance dose schedule, may bemore suitable
to evaluate the effect of vitamin D administration in ICU patients.
Most of the intervention studies in ICU patients also showed
no effect on plasma concentrations of markers of immune func-
tion and inflammatory or pro-inflammatory markers such as
cathelicidin, interleukin 6 (IL-6), C-reactive protein and procalci-
tonin, measured 6 h to 14 d after (the start of) vitamin D admin-
istration(105,119,121,123,131). However, Leaf(126) demonstrated that
1,25(OH)2D administration increased the leucocyte mRNA
expression of cathelicidin and interleukin-10 in sepsis patients.
Quraishi(120), also in a study with sepsis patients given enteral
vitamin D (400,000 IU as a bolus), found an increase in plasma
cathelicidin and a decrease in IL-6 after 5 d. This study also
reported a range of other inflammation markers (e.g. C-reactive
protein, TNF-α and IFN-γ), which were unchanged. This may
potentially reflect that, during severe illness, other drivers of
inflammation have a predominant effect.
The dose–response to vitamin D administration in ICU
patients is poorly characterised and not formally subjected to
meta-analyses. Studies have shown that the response to vitamin
D and 25(OH)D given both orally and intravenously to ICU
patients is blunted compared with healthy people(105). This is
likely a result of impaired hepatic conversion, increased renal
losses and a more rapid catabolism. In generally healthy older
people, vitamin D supplementation at high bolus dosages
appears not to have beneficial effects comparedwith lower daily
or weekly dosages, but has a disadvantageous pharmacokinetic




In addition, it may increase the risk of hypercalcaemia and
hypercalciuria(15). This appears to be a limited issue in ICU
patients. Meta-analyses of the occurrence of hypercalcaemia
in RCTs in ICU patients showed no increased risk after supple-
mentation with high dosages of vitamin D(127). Plasma
1,25(OH)2D concentrations increased with supplementation
and were well over the normal reference range in some
patients(98,104,119,126), but were not associated with hypercalcae-
mia. This is in line with the observation that hypercalcaemia is
relatively uncommon and hypocalcaemia is frequently observed
in ICU patients(35,134). A decrease in total calcium is thought to be
partly an adaptive response to maintain the biologically active
fraction, ionised calcium, constant in the presence of a decrease
in plasma binding proteins, the concentrations of which
decrease with acute and critical illness. However, also the ion-
ised calcium concentration is often below normal ranges with
sepsis and other acute inflammatory illnesses. Although mortal-
ity rates are higher in patients with sepsis with hypocalcaemia,
replacement therapy is not associated with improved
outcomes(134).
Current research investigates the effects of administration of
the pharmaceutical form of 25(OH)D, calcifediol and active vita-
min D or analogues in critically ill patients(105,135,136). With these
forms, the consequences of impaired absorption and activation
of native vitamin Dmay be reduced. Patients with intestinal mal-
function, fat malabsorption and poor liver function may benefit
more from supplementation with 25(OH)D. The absorption of
this form does not depend on fat absorption or the formation
of chylomicrons, does not require hepatic hydroxylation and
leads to a faster and proportionally higher increment in plasma
25(OH)D per unit given compared with vitamin D(71,137–140). In
addition, limited evidence in CKD stage 2–4 patients has shown
that administration of the slow-release formulation of 25(OH)D
is not associatedwith an increase in FGF23(141,142), observedwith
higher dosages of oral vitamin D(143). This may be of particular
importance for severely ill patients since, in many, production
of renal and possibly extra-renal 1,25(OH)2D is impeded due
to renal impairment and increased catabolism, as described in
the previous section. To date, the availability of this form is, how-
ever, limited. In patients with renal impairment and AKI, admin-
istration of active vitamin D or analogues may be considered,
similar to those for patients with CKD. A combinationwith native
vitamin D to ensure tissue availability of 25(OH)D for extra-renal
hydroxylation may be beneficial in this group(135,144).
Together, the contrasting findings between observational,
mechanistic and intervention studies suggest that many factors
other than vitamin D status and intake play a role. The extensive
alterations of vitamin D metabolism with disease processes may
influence its function.With acute and severe illness, other drivers
and regulatory factors of the immune and inflammatory response
may be predominant and may be determined by alterations in
organ function and tissue damage.
Implications for practice
Prevention of vitamin D deficiency and population
guidelines
Thresholds for vitamin D deficiency for the general population
differ between advisory bodies, but most define plasma
25(OH)D values below 25–30 nmol/L as deficient (reviewed
in Refs.(23–25,145)). There is considerable variation between health
authorities in the definition and thresholds or ranges of 25(OH)D
concentration that encompasses vitamin D sufficiency or target
ranges of 25(OH)D on which to base dietary recommenda-
tions(25,145). Recommended 25(OH)D target concentrations and
thresholds for deficiency for specific patient groups and clinical
management may be higher than for generally healthy people
(reviewed in Refs.(25,145)).
The threshold for deficiency is the concentration of 25(OH)D
below which the risk of disease increases. This is predominantly
based on health outcomes related to calcium metabolism and
musculoskeletal health, but in some guidelines also other health
outcomes are considered. Although vitamin D deficiency is asso-
ciated with many other health outcomes, discordant findings
between observational studies and RCTs of vitamin D treatment
are reported. An overview is beyond the scope of thismanuscript
and reviewed elsewhere(26–28).
Population guidelines for dietary vitamin D intakes are partly
based on the required intakes to prevent vitamin D deficiency or
to achieve pre-defined target ranges of 25(OH)D or sufficiency.
Also evidence fromRCTs and other research designs linking vita-
min D intake and status to health outcomes are considered.
Dietary reference values or equivalents, defined by different
public health institutes, vary as a consequence of differences
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in the defined threshold for deficiency, sufficiency or target val-
ues for 25(OH)D (reviewed in Refs.(25,145)). Guidelines for
dietary intakes and supplementation also depend on age group,
physiological state, risk factors (as per below) and, in some
countries, season. An overview of population guidelines from
health authorities across the world was recently published by
Bouillon(145). In most guidelines, it is acknowledged that the
majority of people do not consume sufficient vitamin D through
diet alone and, thus, supplementation is needed to meet require-
ments. In most guidelines, a contribution of cutaneous synthes-
ised vitamin D is taken into account in the formulation of
recommendations of dietary requirements. Advice on sunshine
exposure to maintain vitamin D status is generally not provided
in view of the variability in the response to cutaneous exposure
and the risk of skin damage.
In temperate climates, supplementation is recommended
during winter months. Supplementation throughout the year is
recommended for pregnant women and people at increased risk
of deficiency. At risk are population groupswith a dark skin tone,
obesity and limited skin exposure to the sun (i.e. with a habitual
dress style that covers most of the body, frequent sunscreen use,
limited access to the outdoors, e.g. when mobility is limited or
living in residential care and during illness). It seems appropriate
to also apply this recommendation to those that are in prolonged
self-isolation and therefore mostly indoors. Screening of vitamin
D status is not recommended for the general population. This is
limited to individuals at increased risk of deficiency (as described
above) or who are symptomatic(15,23,145).
Symptoms and correction of vitamin D deficiency
The main manifestation of severe vitamin D deficiency is osteo-
malacia in adults and rickets in children. It is associated with sec-
ondary hyperparathyroidism, bone loss, muscle weakness, falls
and fragility fractures and, in children, also cardiomyopathy and
hypocalcaemia. Clinical symptoms of vitamin D deficiency are
non-specific and include generalised muscle, joint and bone
pain and hyperalgesia, fatigue and muscle weakness, especially
of the extremities and pelvic region, manifesting in difficulties in
rising from a sitting or squatting position or a waddling gait(146)
(https://www.endocrinology.org/media/3593/nos_vitamin_d_
and_bone_-health_in_adults_web.pdf).
When vitamin D deficiency is present (ideally assessed on
basis of plasma 25(OH)D), or strongly suspected on the basis
of clinical symptoms in combination with primary risk factors
(see previous sections), higher intakes than daily population
requirements are required. Recommendations for dosage regi-
mens depend on local health authorities and specific patient
characteristics and target ranges for 25(OH)D (see section
below). In the UK, an intake of 800 IU/d is advised when vitamin
D deficiency is mild and correction is not urgently required. This
approach does not generally require clinical testing andmanage-
ment. When rapid correction of deficiency is needed, such as in
patients with severe deficiency or with symptomatic disease, the
recommended treatment regimen is based on fixed loading
doses followed by maintenance therapy. Loading regimens
aim to provide a total of approximately 300,000 IU given over
a period of 6–10 weeks as weekly or daily split doses.
Similarly, the US Endocrine Society recommends a loading dose
of 300,000–400,000 IU given over 8 weeks(145,147). Maintenance
regimens recommend intakes of 800–2000 IU daily (up to a
maximum of 4000 IU daily), given either daily or intermittently
at a higher equivalent dose. Treatment with these higher dosage
schedules should be monitored with appropriate clinical testing
and management. Large loading dosages exceeding 60,000 IU
given at once should be avoided (https://cks.nice.org.uk/
topics/vitamin-d-deficiency-in-adults-treatment-prevention and
www.endocrinology.org/media/3593/nos_vitamin_d_and_
bone_-health_in_adults_web.pdf)(145,147). High bolus dosages
are associated with an increased risk of falling in adults. In addi-
tion, higher dosages, including when given as a bolus, have a
different and potentially disadvantageous pharmacokinetic pro-
file(71,148); with a high bolus dose, the plasma concentration of
25(OH)D rapidly increases, and there may also be a small
increase in 1,25(OH)2D(149). This is followed by an increase in
catabolism through increased 24-hydroxylation. This is partly
mediated through an increase in FGF23(133,143,150) and
1,25(OH)2D itself(149,151). This results in increased conversion
into 24,25(OH)2D and potentially other catabolic products from
25(OH)D and possibly vitamin D itself. Also, the rate of catabo-
lism of 1,25(OH)2D is expected to increase(133,149,151).
Guidelines for prevention and correction of vitamin D
deficiency in specific patient groups
Recommended intakes, 25(OH)D target concentrations and
thresholds for deficiency for specific patient groups and clinical
management may be higher than for generally healthy peo-
ple(145). They consider altered supply or bio-availability, losses,
increased metabolism and/or requirements or a combination of
these factors. Little is known about the vitamin D requirements
during acute or chronic illness. Even for chronic conditions that
clearly affect vitamin D metabolism (such as renal(144) and
hepatic disease(152–154)) or bioavailability (conditions affecting
intestinal fat and/or vitamin D absorption such as with coeliac
and inflammatory bowel disease(155,156)), direct evidence on
requirements is scarce. Also certain types of medication are asso-
ciated with altered vitamin D metabolism, such as corticoste-
roids, anti-epileptic drugs and drugs inhibiting fat
absorption(145,147) (https://cks.nice.org.uk/topics/vitamin-d-
deficiency-in-adults-treatment-prevention), or increased dietary
calcium requirements, such as medications reducing bone loss.
With these conditions, specific patient management guidelines
should be followed, where formulated (renal(144,25);
hepatic(152–154); coeliac(155); inflammatory bowel disease(156);
osteoporosis (theros.org.uk)). Many guidelines recommend
regular testing of vitamin D status and correction of deficiency
if and as required with monitoring of side effects and until a tar-
get plasma concentration or range of 25(OH)D is reached.
Dependent on the aspect of metabolism affected and severity
or disease, guidelines may recommend prescribing native
vitamin D, 25(OH)D or active vitamin D or their
analogues(144,152–154,157–159).
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Management of vitamin D status in people with acute
and critical illness
Little is known about the vitamin D requirements during acute
and critical illness or with inflammation(23,136).
For patients with mild and short-term acute illnesses, such as
during a mild disease course following infection with SARS-CoV-
2 and/or during self-isolation, supplementationwith vitaminD to
prevent vitamin D deficiency according to population guidelines
for groups with no or limited sun exposure is appropriate(23,145).
In the presence of risk factors or symptoms of deficiency, testing
of vitamin D status and correction of vitamin D deficiency is war-
ranted, as described above.
There is no specific guidance to prevent vitamin D deficiency
in severely ill patients(136). The standard formulations for enteral
feeding contain 200–400 IU vitamin D per day, and parenteral
multivitamin preparations typically contain only 200 or 220 IU
per day. This is below the population recommendations in the
majority of countries. As outlined in previous sections, patients
with acute and critical illness are often vitamin D deficient at
admission and may have a rapid decline in vitamin D status, sug-
gesting that vitamin D requirements are increased. This may be
the result of altered bioavailability or metabolism, increased uti-
lisation and losses of 1,25(OH)2D and 25(OH)D and medication
use increasing catabolism, such as corticosteroids. The most
recent update for critically ill patients recommends screening
of patients for vitamin D deficiency and those with plasma
25(OH)D concentrations below 30 nmol/L to be supplemented
with a single high dose of vitamin D3 (500,000 IU) within a week
after admission(160,161). No guidance is available regarding mon-
itoring, frequency of testing and maintenance therapy.
Considering the likelihood of increased requirements, it seems
reasonable to provide regular (daily or weekly) vitamin D sup-
plementation similar to the maintenance schedules recom-
mended for patients after correction of vitamin D deficiency,
as described above with regular testing of plasma 25(OH)D.
In consideration of underlying conditions and acute altera-
tions in organ function with critical illness, the use of activated
or partly activated vitamin D metabolites may be considered.
Current research investigates the effects of administration of
25(OH)D and active vitamin D in critically ill patients, but this
research is as yet not incorporated in guidelines.
Conclusions
No data are yet available demonstrating a causative link between
low vitamin D status and susceptibility for COVID-19 or its dis-
ease course. Data from observation studies investigating the
association between vitamin D status and risk of infection
and/or developing severe symptoms are conflicting. Vitamin
D deficiency is highly prevalent in patients hospitalised with
COVID-19 and with other conditions, particularly those that
are severely ill. This may be related to the presence of risk factors
for vitamin D deficiency, associated with their general poor
health status or increased catabolism and losses of 25(OH)D dur-
ing disease. There are extensive alterations in vitamin Dmetabo-
lism with severe illness and inflammatory processes which may
increase requirements of vitamin D. This needs consideration in
the assessment of associations with disease risk and severity and
in patient management. Although mechanistic studies show that
vitamin D metabolites and DBP have multi-factorial roles in pul-
monary health, immune function and inflammatory response to
viral infection and tissue damage, supplementation of ICU
patients has so far, however, shown little effect. The contrasting
findings between observational, mechanistic and intervention
studies suggest that many other factors play a role. Alterations
in vitamin D metabolism with disease processes may influence
its function, and/or other drivers of the immune and inflamma-
tory response may be predominant. The effect may depend on
when supplementation is initiated relative to the development of
disease symptoms and progression to severe illness and the fre-
quency of administration. Such data are not yet available. The
beneficial effects of vitamin D may also be limited to specific
subgroups.
There is some evidence that vitamin D supplementation
decreases the risk of respiratory tract infections, particularly in
children, although the risk reduction is moderate. No such evi-
dence is yet available for the prevention or treatment of COVID-
19. In view of the high prevalence of vitamin D deficiency, pro-
actively applying current population and patient management
guidelines to prevent and correct vitamin D deficiency with
screening and monitoring of vitamin D status in individuals
who are at increased risk is appropriate.
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